Sarepta Therapeutics, Inc. (SRPT) shares are falling on Friday morning on disappointing results of its gene-therapy study. The precision genetic medicine research company said its study for the treatment of Duchenne muscular dystrophy did not achieve a statistical significance on the primary functional endpoint of improvement in total NSAA score compared to placebo at 48 weeks post-treatment. Further, the company said 85 percent of the treated group had treatment-related adverse events versus 43 percent in the placebo group.
Currently, shares are at $86.63, down 48.72 percent from the previous close of $168.95 on a volume of 6,611,073. For the 52-week period, the shares have traded in a range of $78.06 to $181.83 on average volume of 781,755.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.